Federated Investors Inc. PA grew its stake in shares of Agilent Technologies Inc (NYSE:A) by 6.1% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 415,280 shares of the medical research company’s stock after acquiring an additional 23,811 shares during the period. Federated Investors Inc. PA owned about 0.13% of Agilent Technologies worth $33,380,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of A. Vanguard Group Inc lifted its position in Agilent Technologies by 0.8% during the third quarter. Vanguard Group Inc now owns 24,155,483 shares of the medical research company’s stock valued at $1,703,929,000 after purchasing an additional 194,607 shares during the period. Artisan Partners Limited Partnership lifted its position in Agilent Technologies by 0.6% during the first quarter. Artisan Partners Limited Partnership now owns 5,858,087 shares of the medical research company’s stock valued at $470,873,000 after purchasing an additional 36,359 shares during the period. Geode Capital Management LLC lifted its position in Agilent Technologies by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock valued at $285,139,000 after purchasing an additional 285,330 shares during the period. Northern Trust Corp lifted its position in Agilent Technologies by 2.0% during the fourth quarter. Northern Trust Corp now owns 3,807,998 shares of the medical research company’s stock valued at $256,888,000 after purchasing an additional 75,416 shares during the period. Finally, Findlay Park Partners LLP acquired a new position in shares of Agilent Technologies in the fourth quarter worth about $246,229,000.
A has been the subject of a number of analyst reports. UBS Group initiated coverage on shares of Agilent Technologies in a research report on Friday, March 15th. They issued a “buy” rating and a $92.00 price objective for the company. Bank of America cut their target price on shares of Agilent Technologies from $88.00 to $82.00 and set a “buy” rating for the company in a research note on Wednesday, May 15th. Deutsche Bank cut their target price on shares of Agilent Technologies from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 15th. Zacks Investment Research cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Finally, Cowen upped their price objective on shares of Agilent Technologies from $80.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Agilent Technologies presently has a consensus rating of “Buy” and an average target price of $86.31.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, May 14th. The medical research company reported $0.71 EPS for the quarter, missing the Zacks’ consensus estimate of $0.72 by ($0.01). The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.65 earnings per share. Equities research analysts forecast that Agilent Technologies Inc will post 3.05 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd will be paid a $0.164 dividend. This represents a $0.66 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Monday, July 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: What defines an oversold asset?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.